Tildrakizumab Indication and Dosing
Tildrakizumab is NOT applicable to all psoriatic patients—it is FDA-approved exclusively for moderate-to-severe plaque psoriasis in adults, not for other psoriasis subtypes. 1
Approved Indication
Tildrakizumab is specifically indicated for:
- Adults only (≥18 years)
- Moderate-to-severe plaque psoriasis
- Patients who are candidates for systemic therapy or phototherapy 2, 1
The drug is NOT approved for:
- Guttate psoriasis
- Erythrodermic psoriasis
- Pustular psoriasis
- Psoriatic arthritis (as monotherapy)
- Mild psoriasis
- Pediatric patients
This is a critical distinction—while other IL-17 inhibitors like ixekizumab have evidence for scalp, nail, erythrodermic, and pustular variants 2, tildrakizumab's approval and evidence base is limited to plaque psoriasis only.
Standard Dosing Schedule (Regardless of Severity)
The FDA-approved dosing regimen is fixed and does NOT vary by disease severity: 1
- 100 mg subcutaneous injection at:
- Week 0 (initial dose)
- Week 4 (second dose)
- Every 12 weeks thereafter (maintenance)
This schedule remains the same whether the patient has moderate or severe disease. The 2019 AAD-NPF guidelines confirm this uniform dosing approach, noting that both 100 mg and 200 mg doses were studied at weeks 0,4, and every 12 weeks thereafter, but the FDA approved only the 100 mg dose as standard 2.
Dose Escalation Considerations
While the standard dose doesn't change with severity, dose escalation to 200 mg may be considered in specific circumstances: 2
- Inadequate primary response after 12 weeks of continuous therapy
- Patients with high body weight (>90 kg) or obesity (BMI ≥25) 3, 4, 5
- Severe disease burden or high-impact area involvement 4, 5
- Prior biologic failure (especially ≥2 biologics or IL-23p19 inhibitor failure) 4
However, this 200 mg dose may be off-label and not funded in many settings 6.
Response Assessment Timeline
Definitive response to tildrakizumab should be assessed at 12 weeks of continuous therapy 2. This is the critical timepoint for determining:
- Primary treatment success or failure
- Need for dose escalation
- Consideration of adjunctive therapies (topical corticosteroids, vitamin D analogues, methotrexate, or UVB light)
Important Clinical Caveats
Pre-treatment requirements:
- Evaluate for tuberculosis infection before initiating 1
- Complete age-appropriate immunizations 1
- Avoid in patients with active infections 1
Administration specifics:
- Must be administered by a healthcare provider (in-office) 2, 1
- Not self-administered like some other biologics
- Allow syringe to reach room temperature for 30 minutes before injection 1
Contraindications:
The quarterly (every 12 weeks) maintenance dosing may improve adherence in elderly patients compared to more frequent dosing schedules 7, but the in-office administration requirement is a practical consideration for treatment planning.